Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes

Stem Cell Research

Volumn 10, Issue 1, 2013, Pages 48-56

  Braam, S R ^a,b   Tertoolen, L ^b   Casini, S ^b   Matsa, E ^c   Lu, H R ^d   Teisman, A ^d   Passier, R ^b   Denning, C ^c   Gallacher, D J ^d   Towart, R ^d   Mummery, C L ^b  

^a Pluriomics BV   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; DILTIAZEM; DOFETILIDE; JNJ 303; LEMAKALIM; MOXIFLOXACIN; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; SOTALOL; SPARFLOXACIN; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; CELL ASSAY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; EMBRYO; GENETIC MODEL; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; MICROELECTRODE; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ACTION POTENTIALS; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PLURIPOTENT STEM CELLS; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SOTALOL; SULFONAMIDES;

EID: 84867602223     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2012.08.007     Document Type: Article

References (37)

1. ABBOTT G., Xu X., ROEPKE T. Impact of ancillary subunits on ventricular repolarization. J. Electrocardiol. 2007, 40(6):S42-S46. 10.1016/j.jelectrocard.2007.05.021.
2. Biliczki P., Virag L., Iost N., Papp J.G., Varro A. Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br. J. Pharmacol. 2002, 137(3):361-368. 10.1038/sj.bjp. 0704881.
3. Biliczki P., Girmatsion Z., Brandes R.P., Harenkamp S., Pitard B., Charpentier F., Hébert T.E., et al. Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs α-subunit interaction. Hear. Rhythm. 2009, 6(12):1792-1801. 10.1016/j.hrthm.2009.08.009.
4. Braam S.R., Tertoolen L.L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010, 4(2):107-116. 10.1016/j.scr.2009.11.004.
5. Camm A.J., Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J. Interv. Card. Electrophysiol. 2008, 23(1):7-14. 10.1007/s10840-008-9269-3.
6. Carlson M. Azimilide dihydrochloride. Expert. Rev. Cardiovasc. Ther. 2005, 3(3):387-391. 10.1586/14779072.3.3.387.
7. Costa M., Dottori M., Ng E., Hawes S.M., Sourris K., Jamshidi P., Pera M.F., et al. The hESC line envy expresses high levels of GFP in all differentiated progeny. Nat. Methods 2005, 2(4):259-260. 10.1038/nmeth748.
8. Davies M.P., Freeman L.C., Kass R.S. Dual actions of the novel class III antiarrhythmic drug NE-10064 on delayed potassium channel currents in guinea pig ventricular and sinoatrial node cells. J. Pharmacol. Exp. Ther. 1996, 276(3):1149-1154.
9. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2003, 2(6):439-447. 10.1038/nrd1108.
10. Guérard N.C., Traebert M., Suter W., Dumotier B.M. Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J. Pharmacol. Toxicol. Methods 2008, 58(1):32-40. 10.1016/j.vascn.2008.05.129.
11. Jost N., Virag L., Bitay M., Takacs J., Lengyel C., Biliczki P., Nagy Z., et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 2005, 112(10):1392. 10.1161/CIRCULATIONAHA.105.550111.
12. Kaab S., Hinterseer M., Näbauer M., Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur. Hear. J. 2003, 24(7):649-657.
13. Lacerda A.E., Kuryshev Y.A., Chen Y., Renganathan M., Eng H., Danthi S.J., Kramer J.W., et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J. Pharmacol. Exp. Ther. 2008, 324(2):427-433. 10.1124/jpet.107.128405.
14. Lengyel C., Iost N., Virág L., Varró A., Lathrop D.A., Papp J.G. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br. J. Pharmacol. 2001, 132(1):101-110. 10.1038/sj.bjp. 0703777.
15. Letsas K.P., Alexanian I.P., Pappas L.K., Kounas S.P., Efremidis M., Sideris A., Kardaras F. QT interval prolongation and torsade de pointes associated with indapamide. Int. J. Cardiol. 2006, 112(3):373-374. 10.1016/j.ijcard.2005.07.055.
16. Li G.R., Feng J., Yue L., Carrier M., Nattel S. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ. Res. 1996, 78(4):689-696.
17. Lin E.C., Holzem K.M., Anson B.D., Moungey B.M., Balijepalli S.Y., Tester D.J., Ackerman M.J., et al. Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(6):H1842-H1849. 10.1152/ajpheart.01236.2009.
18. Lu H.R., Vlaminckx E., Gallacher D.J. Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation. J. Pharmacol. Toxicol. Methods 2008, 57(1):1-8. 10.1016/j.vascn.2007.06.005.
19. Lu H.R., Vlaminckx E., Hermans A.N., Rohrbacher J., van Ammel K., Towart R., Pugsley M., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 2008, 154(7):1427-1438. 10.1038/bjp. 2008.191.
20. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Hear. J. 2011, 10.1093/eurheartj/ehr073.
21. Moss A.J., Shimizu W., Wilde A.A.M., Towbin J.A., Zareba W., Robinson J.L., Qi M., et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007, 115(19):2481-2489. 10.1161/CIRCULATIONAHA.106.665406.
22. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., van der Heyden M., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107(21):2733-2740. 10.1161/01.CIR.0000068356.38592.68.
23. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 2005, 85(4):1205-1253. 10.1152/physrev.00002.2005.
24. Obeyesekere M.N., Klein G.J., Modi S., Leong-Sit P., Gula L.J., Yee R., Skanes A.C., et al. How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia. Circ. Arrhythm. Electrophysiol. 2011, 4(6):958-964. 10.1161/CIRCEP.111.965947.
25. Passier R., Ward-van Oostwaard D., Snapper J., Kloots J., Hassink R.J., Kuijk E., Roelen B., et al. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 2005, 23(6):772-780. (Dayton, Ohio). 10.1634/stemcells.2004-0184.
26. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999, 99(4):529-533.
27. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin. Electrophysiol. 1998, 21(5):1029-1034.
28. Roden D.M. Repolarization reserve: a moving target. Circulation 2008, 118(10):981-982. 10.1161/CIRCULATIONAHA.108.798918.
29. Roden D.M., Viswanathan P.C. Genetics of acquired long QT syndrome. J. Clin. Invest. 2005, 115(8):2025-2032. 10.1172/JCI25539.
30. Shah R.R. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br. J. Pharmacol. 2010, 159(1):58-69. 10.1111/j.1476-5381.2009.00191.x.
31. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., Heath B.M. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J. Pharmacol. Toxicol. Methods 2006, 56(2):171-185. 10.1016/j.vascn.2007.04.005.
32. Terrenoire C., Houslay M.D., Baillie G.S., Kass R.S. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J. Biol. Chem. 2009, 284(14):9140-9146. 10.1074/jbc.M805366200.
33. Thomas G.P., Gerlach U., Antzelevitch C. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J. Cardiovasc. Pharmacol. 2003, 41(1):140.
34. Towart R., Linders J., Hermans A., Rohrbacher J., van der Linde H., Ercken M., Cik M., et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?. J. Pharmacol. Toxicol. Methods 2009, 10.1016/j.vascn.2009.04.197.
35. Varro A., Baczkó I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br. J. Pharmacol. 2011, 164(1):14-36. 10.1111/j.1476-5381.2011.01367.x.
36. Varró A., Baláti B., Iost N., Takács J., Virág L., Lathrop D.A., Csaba L., et al. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol. 2000, 523(Pt 1):67. 10.1111/j.1469-7793.2000.00067.x.
37. Volders P.G.A., Stengl M., van Opstal J.M., Gerlach U., Spätjens R.L.H.M.G., Beekman J.D.M., Sipido K.R., et al. Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation. Circulation 2003, 107(21):2753-2760. 10.1161/01.CIR.0000068344.54010.B3.